Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
521. |
ECCT/25/03/03 | ALIM STUDY Evaluating the safety and efficacy of Imatinib in combination with Artemether and Lumefantrine for the treatment of Uncomplicated Malaria: a three-part trial. |
Principal Investigator(s) 1. Dr. QUENTIN AWORI Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
27-10-2025 |
View |
522. |
ECCT/25/07/05 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studie |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Elgeyo/Marakwet county) 3. KEMRI-WRP (Kericho county) 4. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
31-10-2025 |
View |
523. |
ECCT/25/07/06 | SASI Randomized Controlled Trial of Surfactant Administered via Supraglottic Airway Device (SALSA) Compared to Endotracheal Tube (InSurE) on Survival without Mechanical Ventilation in Preterm Neonates with Respiratory Distress Syndrome in Sub-Saharan Africa |
Principal Investigator(s) 1. Mary Waiyego Kariuki Site(s) in Kenya Kenyatta national Hospital |
31-10-2025 |
View |
524. |
ECCT/25/04/04 | LIMIT A Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) |
Principal Investigator(s) 1. Anthony KIBUKA Gikonyo Site(s) in Kenya The Karen Hospital |
12-11-2025 |
View |
525. |
ECCT/24/10/06 | A5409 A Phase 2, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. KEMRI/WRP CRS (Kericho county) |
18-11-2025 |
View |
526. |
ECCT/25/05/07 | Floral roll over study An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Prof Jessie Githanga Site(s) in Kenya 1. Gertrudes Childrens Hospital (Nairobi City county) 2. KEMRI Kondele Children\'s Hospital (Kisumu county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 5. KEMRI WALTER REED KERICHO (Kericho county) 6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 7. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) |
21-11-2025 |
View |
527. |
ECCT/25/06/03 | ZHR-001 Physiological and Biomarker Monitoring: Enhancing Vital Signs and Biomarkers Algorithm of Binah.AI in the Kenyan Population |
Principal Investigator(s) 1. Borna Achieng Nyaoke Site(s) in Kenya Zuri Health Medical Centre |
21-11-2025 |
View |
528. |
ECCT/25/08/01 | MK-8527 as HIV-1 PrEP in Women A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women |
Principal Investigator(s) 1. Maricianah Onono Site(s) in Kenya 1. KEMRI-RCTP KISUMU (Kisumu county) 2. Kargeno Research and Policy Hub KEMRI-CMR KISUMU (Kisumu county) 3. KEMRI-PHRD, Thika (Kiambu county) 4. UW KNH - Rachuonyo County Hospital (Homa Bay county) |
21-11-2025 |
View |
529. |
ECCT/25/08/02 | MK-8527-010 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women. |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya 1. KEMRI CMR RCTP (Kisumu county) |
21-11-2025 |
View |
530. |
ECCT/25/05/03 | Hibiscus 2 - Site 253 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Site 253 - International Cancer Institute (Uasin Gishu county) |
25-11-2025 |
View |